Calcification of surgical aortic bioprostheses and its impact on clinical outcome.

aortic valve calcification computed tomography echocardiography structural valve degeneration surgical aortic valve bioprostheses

Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 11 08 2023
revised: 01 02 2024
accepted: 25 03 2024
medline: 12 4 2024
pubmed: 12 4 2024
entrez: 12 4 2024
Statut: aheadofprint

Résumé

Aortic valve calcification (AVC) of surgical valve bioprostheses (BP) has been poorly explored. We aimed to evaluate in-vivo and ex-vivo BP AVC and its prognosis value. Between 2011 and 2019, AVC was assessed using in-vivo computed tomography (CT) in 361 patients who had undergone surgical valve replacement 6.4±4.3 years earlier. Ex-vivo CT scans were performed for 37 explanted BP. The in-vivo CT scans were interpretable for 342 patients (19 patients [5.2%], were excluded). These patients were 77.2±9.1 years old and 64.3% were male. Mean in-vivo AVC was 307±500 Agatston unit (AU). The AVC was 562±570 AU for the 183 (53.5%) patients with structural valve degeneration (SVD) and 13±43 AU for those without SVD (p<0.0001). In-vivo and ex-vivo AVC were strongly correlated (r=0.88, p<0.0001). An in-vivo AVC>100 AU (n=147, 43%) had a specificity of 96% for diagnosing Stage 2-3 SVD (area under the curve=0.92). Patients with AVC>100 AU had a worse outcome compared with those with AVC≤100 AU (n=195). In multivariable analysis, AVC was a predictor of overall mortality (hazard ratio [HR] and 95% confidence interval=1.16[1.04-1.29]; p=0.006), cardiovascular mortality (HR=1.22[1.04-1.43]; p=0.013), cardiovascular events (HR=1.28 [1.16-1.41]; p<0.0001), and re-intervention (HR=1.15 [1.06-1.25]; p<0.0001). After adjustment for Stage 2-3 SVD diagnosis, AVC remained a predictor of overall mortality (HR=1.20 [1.04-1.39]; p=0.015) and cardiovascular events (HR=1.25 [1.09-1.43]; p=0.001). CT scan is a reliable tool to assess BP leaflet calcification. An AVC>100 AU is tightly associated with SVD and it is a strong predictor of overall mortality and cardiovascular events.

Identifiants

pubmed: 38606926
pii: 7644670
doi: 10.1093/ehjci/jeae100
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Guillaume Guimbretière (G)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Thomas Sénage (T)

L'institut du thorax, CHU Nantes, Nantes, France.
INSERM UMR 1246 - SPHERE, Nantes University, Tours University, Nantes, France.

Anne-Sophie Boureau (AS)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Jean-Charles Roos (JC)

L'institut du thorax, CHU Nantes, Nantes, France.

Quentin Bernard (Q)

L'institut du thorax, CHU Nantes, Nantes, France.

Baptiste Carlier (B)

L'institut du thorax, CHU Nantes, Nantes, France.

Joelle Veziers (J)

INSERM, UMR 1229, RMeS, CHU Nantes, PHU4 OTONN, UNIV Nantes, Nantes, France.
UFR Odontologie, SC3M Plateform, UMS INSERM 016 - CNRS 3556, SFR François Bonamy, Nantes, France.

Caroline Cueff (C)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Nicolas Piriou (N)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Guenola Coste (G)

L'institut du thorax, CHU Nantes, Nantes, France.

Imen Fellah (I)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Coline Lelarge (C)

L'institut du thorax, CHU Nantes, Nantes, France.

Romain Capoulade (R)

L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Philippe Jaafar (P)

L'institut du thorax, CHU Nantes, Nantes, France.

Thibaud Manigold (T)

L'institut du thorax, CHU Nantes, Nantes, France.

Vincent Letocart (V)

L'institut du thorax, CHU Nantes, Nantes, France.

Karine Warin-Fresse (K)

L'institut du thorax, CHU Nantes, Nantes, France.

Patrice Guérin (P)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Cristina Costa (C)

Infectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, L'Hospitalet de Llobregat, Barcelona, Spain.

Marta Vadori (M)

Transplant Immunology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Padua University Hospital, Padua, Italy.

Manuel Galinañes (M)

Department of Cardiac Surgery and Reparative Therapy of the Heart, Vall d'Hebron Research Institute (VHIR), University Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Rafael Manez (R)

Infectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, L'Hospitalet de Llobregat, Barcelona, Spain.

Jean-Paul Soulillou (JP)

INSERM, UMR 1064, ITUN, CHU Nantes, Nantes, France; UNIV Nantes, Nantes, France.

Emanuele Cozzi (E)

Transplant Immunology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Padua University Hospital, Padua, Italy.

Vered Padler-Karavani (V)

Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.

Jean-Michel Serfaty (JM)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Jean-Christian Roussel (JC)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Thierry Le Tourneau (T)

L'institut du thorax, CHU Nantes, Nantes, France.
L'institut du thorax, INSERM UMR 1087, CNRS, UNIV Nantes, Nantes, France.

Classifications MeSH